AI-generated summary
The authors report laboratory studies in mice, cultured cells and rat eyes, plus an open-label Phase IIa trial in 21 patients with centre-involving diabetic macular oedema treated with 670 nm light. They found reductions in central macular thickness at 2 and 6 months and report the treatment was well tolerated. The trial was small, open-label and had no control group, so the authors call for randomised trials.
- Participants
- 21
- Who or what was studied
- Patients with centre-involving diabetic macular oedema recruited from Sydney Eye Hospital, plus transgenic mice, cultured rat Müller cells and pigmented and non-pigmented rat eyes
- Wavelengths
- 670 nm
- Limits stated in the abstract
- The clinical trial was small, open-label and dose-escalation with no control group, and the authors state that randomised clinical trials are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 670 nm
- Power density (irradiance)
- 200 mW/cm2, 100 mW/cm2, 25 mW/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Laser, Photobiomodulation therapy, Light-emitting diode, Oxidative stress, Photoreceptor, Trial registration, Retina. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.